Sarcopenia and chemotherapy-mediated toxicity

This narrative review focuses on the role of sarcopenia and chemotherapy-induced toxicity in cancer patients. Consistent evidence shows that sarcopenia in cancer patients leads to decreased overall survival by influencing treatment discontinuation and dose reduction. Therefore, sarcopenia should be...

Descripción completa

Detalles Bibliográficos
Autores principales: Vega, Maria Cecília Monteiro Dela, Laviano, Alessandro, Pimentel, Gustavo Duarte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Israelita de Ensino e Pesquisa Albert Einstein 2016
Materias:
Medical Developments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221390/
https://www.ncbi.nlm.nih.gov/pubmed/28076611
http://dx.doi.org/10.1590/S1679-45082016MD3740
_version_ 1782492800885981184
author Vega, Maria Cecília Monteiro Dela
Laviano, Alessandro
Pimentel, Gustavo Duarte
author_facet Vega, Maria Cecília Monteiro Dela
Laviano, Alessandro
Pimentel, Gustavo Duarte
author_sort Vega, Maria Cecília Monteiro Dela
collection PubMed
description This narrative review focuses on the role of sarcopenia and chemotherapy-induced toxicity in cancer patients. Consistent evidence shows that sarcopenia in cancer patients leads to decreased overall survival by influencing treatment discontinuation and dose reduction. Therefore, sarcopenia should be considered a robust prognostic factor of negative outcome as well as a determinant of increased healthcare costs.
format Online
Article
Text
id pubmed-5221390
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Instituto Israelita de Ensino e Pesquisa Albert Einstein
record_format MEDLINE/PubMed
spelling pubmed-52213902017-02-03 Sarcopenia and chemotherapy-mediated toxicity Vega, Maria Cecília Monteiro Dela Laviano, Alessandro Pimentel, Gustavo Duarte Einstein (Sao Paulo) Medical Developments This narrative review focuses on the role of sarcopenia and chemotherapy-induced toxicity in cancer patients. Consistent evidence shows that sarcopenia in cancer patients leads to decreased overall survival by influencing treatment discontinuation and dose reduction. Therefore, sarcopenia should be considered a robust prognostic factor of negative outcome as well as a determinant of increased healthcare costs. Instituto Israelita de Ensino e Pesquisa Albert Einstein 2016 /pmc/articles/PMC5221390/ /pubmed/28076611 http://dx.doi.org/10.1590/S1679-45082016MD3740 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Medical Developments
Vega, Maria Cecília Monteiro Dela
Laviano, Alessandro
Pimentel, Gustavo Duarte
Sarcopenia and chemotherapy-mediated toxicity
title Sarcopenia and chemotherapy-mediated toxicity
title_full Sarcopenia and chemotherapy-mediated toxicity
title_fullStr Sarcopenia and chemotherapy-mediated toxicity
title_full_unstemmed Sarcopenia and chemotherapy-mediated toxicity
title_short Sarcopenia and chemotherapy-mediated toxicity
title_sort sarcopenia and chemotherapy-mediated toxicity
topic Medical Developments
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221390/
https://www.ncbi.nlm.nih.gov/pubmed/28076611
http://dx.doi.org/10.1590/S1679-45082016MD3740
work_keys_str_mv AT vegamariaceciliamonteirodela sarcopeniaandchemotherapymediatedtoxicity
AT lavianoalessandro sarcopeniaandchemotherapymediatedtoxicity
AT pimentelgustavoduarte sarcopeniaandchemotherapymediatedtoxicity

Ejemplares similares